Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Conditions: Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy; Pre-transplant Purging
Interventions: Drug: Elranatamab; Drug: Lenalidomide; Drug: Plerixafor; Drug: Melphalan; Drug: Busulfan; Drug: G-CSF; Procedure: Stem cell transplant
Sponsors: M.D. Anderson Cancer Center; Pfizer
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 18, 2024Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments